Dr Reddy's gets DCGI nod for cancer drug's second indication in India
.webp)
Dr Reddy’s Laboratories has received approval from the Drug Controller General of India (DCGI) for its immunotherapy drug Zytorvi (toripalimab) for the first-line treatment of adults with advanced oesophageal squamous cell carcinoma (ESCC), expanding the drug’s use beyond nasopharyngeal cancer in India.
The approval by the Central Drugs Standard Control Organisation (CDSCO) covers the use of toripalimab in combination with the chemotherapy drugs cisplatin and paclitaxel for patients with unresectable advanced, recurrent or metastatic ESCC.
This is the drug’s second approved indication in India, following its launch in November 2024 for recurrent or metastatic nasopharyngeal carcinoma.
Dr Reddy’s has exclusive rights to develop and commercialise toripalimab in 21 countries under a licensing agreement signed with Shanghai Junshi Biosciences in 2023.
The approval for ESCC is supported by results from the Phase III JUPITER-06 clinical trial.
The study found that toripalimab, when administered with chemotherapy, reduced the risk of disease progression or death by 42 per cent compared with chemotherapy alone.
At the final overall survival analysis, median survival was 17.7 months among patients receiving the combination treatment, compared with 12.9 months for those receiving chemotherapy alone.
Clinical benefits were observed across patient groups with different levels of PD-L1 expression, a biomarker used in cancer treatment decisions.
The Indian approval does not require patient selection based on PD-L1 expression, potentially allowing eligible patients to be considered for treatment irrespective of biomarker status.
“Following the approval of Zytorvi in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced oesophageal squamous cell carcinoma,” said M V Ramana, chief executive officer, global generics, Dr Reddy’s Laboratories.
The company’s expansion into ESCC comes amid the significant disease burden in India.
Oesophageal cancer was the fourth-leading cause of cancer-related deaths in the country in 2024, accounting for approximately 8.1 per cent of such deaths, according to the company, citing estimates from the International Agency for Research on Cancer.
ESCC accounts for around 80 per cent of oesophageal cancer cases in India.
Toripalimab is a humanised monoclonal antibody that targets programmed death receptor-1 (PD-1), a protein involved in regulating immune responses.
By blocking the interaction between PD-1 and its ligands, the drug helps enable T-cells to attack cancer cells.
Globally, toripalimab has received approvals from regulators including the US Food and Drug Administration, the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency.
Other Latest News
.webp)
The Delhi High Court Wednesday said it will hear on October 22 All India Students' Association (AISA) President Neha Bora's plea against a Delhi Police notice asking her to execute a "peace" bond before a Special Executive Magistrate (SEM).
Bora, who has been at the forefront of protests against the alleged irregularities in the Election Commission's Special Intensive Revision (SIR) of electoral rolls.
.webp)
The Delhi High Court on Wednesday refused to interfere with the judicial custody of Cockroach Janta Party leaders Saurav Das and Ashutosh Ranka, as it asked them to await the outcome of the hearing scheduled before the Special Executive Magistrate (SEM), and approach the appellate court if their grievance continues.
The hearing before the SEM is scheduled later in the day.
.webp)
An internal probe by HDFC Bank Ltd. — India’s largest by market value — found evidence that two senior executives disclosed confidential business strategies and possible market-sensitive information to outsiders, according to people familiar with the matter.
The executives oversee certain key businesses and functions at the bank, according to the people, who asked not to be named discussing confidential matters.
.webp)
The State Bank of India (SBI), the country’s largest lender, has flagged suspected exposure of customer data on the dark web, with a preliminary analysis identifying 3,897 customer records containing personally identifiable information (PII), according to a disclosure to the stock exchanges.
The bank received alerts on October 16 from its threat intelligence service provider.
.webp)
Reliance Industries’ digital arm Jio Platforms’ initial public offering (IPO) was subscribed 1.01 times at around 10:34 am on Wednesday, the opening day of the issue, with bids for about 19.99 crore shares worth roughly Rs 22,354 crore at the upper end of the price band, against Rs 22,078 crore worth of shares on offer.
Qualified institutional buyers (QIBs) led demand, bidding 3.25 times their reserved portion, with bids worth Rs 17,804 crore against Rs 5,484 crore on offer, according to exchange data.
.webp)
.webp)
.webp)
.webp)
.webp)
